Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.
Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.
Yan Y, et al.
EMBO Mol Med. 2018 Apr;10(4):e8478. doi: 10.15252/emmm.201708478.
EMBO Mol Med. 2018.
PMID: 29523594
Free PMC article.